Stayble Therapeutics

Stayble's CEO, Andreas Gerward, presented the latest news and the exciting upcoming months at Aktiedagarna in Stockholm yesterday (17/9). Watch the recorded presentation using the following link (in Swedish): https://lnkd.in/d2VZKdcc

The last patient visit has been completed in our phase 1b study involving patients with pain caused by herniated discs. We follow the communicated timeline and expect to present study results during the fourth quarter of 2024. CEO Andreas Gerward commented: "I am very proud that we have conducted our clinical study according to plan and have exceeded our goal regarding the number of patients who completed all their visits. We are now approaching the most exciting part – reviewing the study results. However, before that, the collected data needs to be verified and quality-checked, after which data analysis can produce and compile the results. We estimate this will take about three months. During this period, we will intensify dialogues with potential partners." Read more: https://lnkd.in/dyYZ5RPX

All patients included in Stayble Therapeutics' phase Ib study in disc hernia with STA363. Andreas Gerward, CEO, comments: "The fact that we have now included the last patient is a significant step forward in this important phase Ib study. The study has gone according to schedule without delay, which we are very proud of. Clinical development has its challenges, but we, together with our subcontractor and investigators, have carried out successful patient recruitment. I now look forward to the next study stage and to report the results in Q4 2024.” Read more at: https://lnkd.in/dwGDQuKk

Since the release of the topline results, Stayble Therapeutics has conducted further analyses of the data. Last week, we announced that the analyses provide significant support for their herniated disc project. BioStock contacted CEO Andreas Gerward who shared his thoughts and provided further details about the findings and what they mean for the future of herniated disc treatments. Read the full article here: https://lnkd.in/du8RhccP #discherniation #backpain

New insights from Stayble!   Data from Stayble's Phase IIb study strengthens the foundation of our treatment for herniated discs. From our latest analysis, we observed that patients administered with a higher dosage of STA363 showed a notable change in both disc intensity and height. This reduction in disc volume is expected to result in decreased herniation size, potentially leading to reduced pain in those suffering from herniated discs. Discover more in the full press release: https://lnkd.in/eQkmNVY9 #herniateddiscs #backpain

Stayble Therapeutics shifts focus to phase Ib study in disc herniation! Following recent events, our CEO, Andreas Gerward, met with BioStock and shared his insights about the future plans for Stayble. Discover more by following the link: https://lnkd.in/eqpmMwjA  BioStock - Connecting Innovation and Capital #backpain #clinicaltrial #herniateddisc 

The interim report for the third quarter is now available! Stayble Therapeutics has published its interim report for the third quarter of 2023. Comment from our CEO, Andreas Gerward: “We at Stayble aim for every shareholder to clearly understand the differences between our two different indications. From now on, we will carefully analyze the data from the phase 2b study. We plan to update the market with more detailed information on all the data and explain why our belief in the potential of the herniated disc project still remains.” Explore the full report by following the link: https://lnkd.in/emAFbjw5  

Stayble is approaching the disclosure of the Phase IIb study results! Stayble Therapeutics is on track to present top-line data from the Phase IIb study of STA363, aimed at treating degenerative disc disease. The anticipated results are set to be shared within the next month, with a target of November or early December. For more information on this significant milestone, read BioStock's latest article here: https://lnkd.in/eY9Yianm #backpain #Chronic_Back_Pain #clinicaltrial #degenerativediscdisease #healthcare BioStock - Connecting Innovation and Capital